PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

0
Player Avatar titans8904 (69.84) Submitted: 9/27/2011 10:11:42 AM : Outperform Start Price: $5.59 PDLI Score: +4.41

Great company

Report this Post Reply

Featured Broker Partners


Advertisement